GoodRx (GDRX) Scheduled to Post Quarterly Earnings on Thursday

GoodRx (NASDAQ:GDRX) will be issuing its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of $0.09 per share for the quarter. GoodRx has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Investors interested in participating in the company’s conference call can do so using this link.

GoodRx (NASDAQ:GDRX) last released its earnings results on Thursday, August 8th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). The business had revenue of $200.60 million for the quarter, compared to the consensus estimate of $200.47 million. GoodRx had a negative net margin of 7.57% and a positive return on equity of 3.63%. The firm’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.02 EPS. On average, analysts expect GoodRx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

GoodRx Stock Down 5.2 %

GoodRx stock opened at $5.87 on Tuesday. The company has a 50-day simple moving average of $7.10 and a 200-day simple moving average of $7.55. The firm has a market capitalization of $2.23 billion, a P/E ratio of -45.15, a P/E/G ratio of 3.86 and a beta of 1.39. The company has a debt-to-equity ratio of 0.96, a quick ratio of 7.32 and a current ratio of 7.32. GoodRx has a one year low of $4.14 and a one year high of $9.26.

Insider Buying and Selling

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total value of $83,921.22. The transaction was disclosed in a filing with the SEC, which is available at this link. 4.17% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages recently issued reports on GDRX. UBS Group decreased their target price on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a research report on Friday, August 9th. Citigroup cut their price target on shares of GoodRx from $11.00 to $10.00 and set a “buy” rating for the company in a report on Friday, August 9th. Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 price target on shares of GoodRx in a report on Friday, August 16th. Finally, Raymond James raised shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price target for the company in a report on Friday, August 9th. One analyst has rated the stock with a sell rating, four have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, GoodRx has a consensus rating of “Moderate Buy” and an average price target of $9.36.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.